Cover Image
市場調查報告書

人免疫力缺乏病毒 (HIV) :主要8市場預測

HIV Forecast in 8 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 371913
出版日期 內容資訊 英文 42 pages
訂單完成後即時交付
價格
Back to Top
人免疫力缺乏病毒 (HIV) :主要8市場預測 HIV Forecast in 8 Major Markets 2016-2026
出版日期: 2016年09月27日 內容資訊: 英文 42 pages
簡介

本報告提供主要8個市場 (美國、法國、德國、義大利、西班牙、英國、巴西、日本) 的人免疫力缺乏病毒 (HIV)的目前患者數 (性別,各年齡世代) 調查分析,目前盛行率,加上疾病概要,危險因素,疾病診斷預後,主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

疾病相關的主要併發症/特徵

患者數的定量化方法

人免疫力缺乏病毒 (HIV)的最大患病人數

人免疫力缺乏病毒 (HIV) 患者的特徵

  • HIV與診斷
  • HIV和確診患者的併發症

簡稱

相關出版

病患人數的線上資料庫

病患人數的產品

線上價格資料、平台

參考文獻

附錄

目錄

The human immunodeficiency virus (HIV) is a lentivirus that causes chronic viral infection. HIV damages the immune system and prevents the body from fighting off the organisms that cause infection and disease. Without early diagnosis and treatment of HIV, the body can go on to develop AIDS. Acquired immunodeficiency syndrome (AIDS) is the final stage of HIV. The development of AIDS interferes with the body's ability to fight off any life threatening infection.

HIV is most commonly a sexually transmitted infection. However, it can also be contracted through contact with infected blood or from mother to child during pregnancy, childbirth or breast feeding (vertical transmission).

This report provides the current prevalent population for HIV across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HIV have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HIV include:

  • Impaired kidney function
  • AIDS
  • Opportunistic infections
  • HBC
  • HCV

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global HIV market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of HIV and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on the HIV prevalent population.
  • Identify sub-populations within HIV which require treatment.
  • Gain an understanding of the specific markets that have the largest number of HIV patients.

Coverage

  • BR
  • FR
  • DE
  • IT
  • JP
  • ES
  • UK
  • US

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line prevalence for HIV
  • Characteristics of HIV patients
  • Diagnosed HIV
  • Comorbid conditions in patients diagnosed with HIV
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Prevalence of HIV, total (000s)
  • Prevalence of HIV, males (000s)
  • Prevalence of HIV, females (000s)
  • PLWHIV Acquisition risk group, total (000s)
  • Diagnosed HIV, total (000s)
  • Diagnosed HIV by Acquisition risk group, total (000s)
  • Newly diagnosed HIV (incident cases), total (000s)
  • Diagnosed HIV patients Seen for care, total (000s)
  • Diagnosed HIV patients treated with ART, total (000s)
  • Ethnic Origin of diagnosed HIV patients, total (000s)
  • Diagnosed HIV patients with CKD, total (000s)
  • Diagnosed HIV patients with CKD by stage, total (000s)
  • Annual cases of AIDS among diagnosed HIV patients, total (000s)
  • Diagnosed HIV patients with HBV co-infection, total (000s)
  • Diagnosed HIV patients with HCV co-infection, total (000s)
  • Diagnosed HIV patients with HCV co-infection by HCV Genotypes, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of HIV by 5-yr age cohort, males (000s)
  • USA Prevalence of HIV by 5-yr age cohort, females (000s)
  • France Prevalence of HIV by 5-yr age cohort, males (000s)
  • France Prevalence of HIV by 5-yr age cohort, females (000s)
  • Germany Prevalence of HIV by 5-yr age cohort, males (000s)
  • Germany Prevalence of HIV by 5-yr age cohort females (000s)
  • Italy Prevalence of HIV by 5-yr age cohort, males (000s)
  • Italy Prevalence of HIV by 5-yr age cohort, females (000s)
  • Spain Prevalence of HIV by 5-yr age cohort, males (000s)
  • Spain Prevalence of HIV by 5-yr age cohort, females (000s)
  • UK Prevalence of HIV by 5-yr age cohort, males (000s)
  • UK Prevalence of HIV by 5-yr age cohort, females (000s)
  • Brazil Prevalence of HIV by 5-yr age cohort, males (000s)
  • Brazil Prevalence of HIV by 5-yr age cohort, females (000s)
  • Japan Prevalence of HIV by 5-yr age cohort, males (000s)
  • Japan Prevalence of HIV by 5-yr age cohort, females (000s)
Back to Top